Drug – bio-affecting and body treating compositions – Solid synthetic organic polymer as designated organic active... – Monomer contains oxygen
Patent
1991-08-14
1992-10-06
Rollins, John W.
Drug, bio-affecting and body treating compositions
Solid synthetic organic polymer as designated organic active...
Monomer contains oxygen
514723, A61A 31745
Patent
active
051529793
ABSTRACT:
In accordance with the present invention, a method is provided for treating ischemia resulting from microvascular compromise caused by abnormal cells in the blood stream, which is often a complication of malaria and leukemia. The method is especially useful for treating cerebral malaria. The method comprises administering to an animal or human with the microvascular compromise a therapeutically effective amount of a surface active copolymer with the following general formula:
REFERENCES:
patent: 2674619 (1954-04-01), Lunsted
patent: 3450502 (1960-06-01), Hymes
patent: 3577522 (1971-05-01), Hymes
patent: 3590125 (1971-06-01), Hymes
patent: 3641240 (1972-02-01), Hymes et al.
patent: 3956259 (1976-05-01), Garcia et al.
patent: 3980772 (1976-09-01), Ginger et al.
patent: 4073886 (1978-02-01), Kehm
patent: 4186253 (1980-01-01), Yokoyama et al.
patent: 4395393 (1983-07-01), Schmolka
patent: 4600652 (1986-07-01), Solomon et al.
patent: 4609546 (1986-09-01), Hiratani
Schmolka, I., "A Review of Block Polymer Surfactants", Journal of the American Oil Chemists Society, 54, No. 3, pp. 110-116 (1977).
Block and Graft Copolymerization, vol. 2, (ed. by R. J. Ceresa, John Wiley & Sons, 1976) "The Applications of Block Copolymer Polyol Surfactants"L. G. Lundsted and I. R. Schmolka; pp. 174-205 and pp. 255-272 (references).
Reindorf, C. A., et al., "Perfluorocarbon Compounds: Effects on the Rheological Properties of Sickle Erythrocytes in vitro", American Journal of Hematology, vol. 19, pp. 229-236, (1985).
Padilla, F., et al., "Effect of Fluorocarbon emulsions on the mechanical fragility of normal and sickle cells: in vitro studies" Federation Proceedings, vol. 34, pp. 1510-1512, (1975).
Vercellotti, G. M., et al., "Activation of Plasma Complement by Perfluorocarbon Artificial Blood: Probable Mechanism of Adverse Pulmonary Reactions in Treated Patients and Rationale for Corticosteroid Prophylaxis", Blood, vol. 59, pp. 1299-1304, (1982).
Janoff, A. S., et al., "The Modification of Human Erythrocyte Membrane Structure by Membrane Stabilizers: An Electron Spin Resonance Study", American Journal of Hematology, vol. 10, pp. 171-179, (1981).
Moore, A. R., et al., "Reduction of Splenic Vascular Resistance During Profusion By Pluronic.RTM. F-68", Journal of Surgical Research, vol. 8, pp. 563-566, (1968).
Benner, K. U., et al., "Cold-Induced Platelet Aggregation In Vivo and Its Inhibition By A Nonionic Surface Active Substance", Thrombosis Research, vol. 2, pp. 331-342, (1973).
Hymes, A. C., et al., "The Influence of An Industrial Surfactant Pluronic.RTM. F-68, In the Treatment of Hemorrhagic Shock", Journal of Surgical Research, vol. 11, pp. 191-197, (1971).
Hoie, J., et al., "Effects of pluronic.RTM. F-68, Poloralkol, On Vascular Resistance In Vivo", Journal of Surgical Research, vol. 11, pp. 515-517, (1971).
Grover, F. L., et al., "A Nonionic Surfactant And Blood Viscosity", Arch. Surg., vol. 106, pp. 307-310, (1973).
Grover, F. L., et al., "The Effect of Pluronic.RTM. F-68 On Circulatory Dynamics and Renal And Carotid Artery Flow During Hemorrhagic Shock", Journal of Surgical Research, vol. 17, pp. 30-35, (1974).
Ketchum, L. D., et al., "Experimental Use of Pluronic .RTM. F-68 In Microvascular Surgery", Plastic and Reconstructive Surgery, vol. 53, pp. 288-292, (1974).
Ketchum, L. D., "Pharmacological alterations in the clotting mechanism: Use in microvascular surgery", Journal of Hand Surgery, vol. 3, pp. 407-415, (1978).
Vasco, K. A., et al., "Poloxalkol.RTM. (Pluronic F-68): A priming solution for cardiopulmonary bypass", Trans. Am. Soc. Artif. Int. Organs, vol. 18, pp. 526-531, (1972).
Block, N. L., et al., "Acutely traumatized canine ureter, Effects of low molecular weight dextran and surfactant Pluronic F-68", Urology, vol. III, pp. 190-194, (1974).
Knize, D. M., et al., "Use of antisludging agents in experimental cold injuries", Surgery, Gynecology & Obstetrics, vol. 129, pp. 1019-1026, (1969).
Organ Perfusion and Preservation, (ed. Norman, J. C., Appleton-Century-Crofts, (1968)), Paton, B. C., et al., "The use of a nonionic detergent added to organ perfusates", pp. 105-120.
Smillie, J. A., et al., "Cryopreservation of Human Platelets with Polyvinylpyrrolidone", Transfusion, vol. 21, pp. 552-556, (1981).
Gaehtgens, P., et al., "Disaggregation of Human Red Blood Cells by Various Surface-Active Agents as Related to Changes of Cell Shape and Hemolysis", Act Heamat., vol. 33, pp. 82-89, (1975).
Advances in Blood Substitute Research (ed. by Bolin, et al., Alan R. Liss, Inc., New York, (1983)) Sugi, et al., The use of Fluosol-DA (FDA) in emergency situations: a report of 67 clinical sases, Abstract/451.
Lane, T. A., et al., "Reduction in the toxicity of a component of an artifical blood substitute by supercritical fluid fractionation", Transfusion, vol. 28, pp. 375-378, (1987).
Lane, T. A., et al., "Paralysis of phagocyte migration due to an artificial blood substitute", Blood, vol. 64, pp. 400-405, (1984).
Spiess, B. D., et al., "Protection from cerebral air emboli with perfluorocarbons in rabbits", Stroke, vol. 17, pp. 1146-1149, (1986).
Kanter, K. R., et al., "Superiority of perfluorocarbon cardioplegia over blood or crystalloid cardioplegia", Circulation, vol. 64, pp. II-75-II-80, (1981).
Harjula, A., et al., "Pefluorocarbon solution as a myocardial preservative", J. Applied Cardiology, vol. 2, pp. 121-136, (1987).
Tokioka, M. D., et al., "Effects of intracoronary infusion of arterial blood or Fluosol-DA 20% on regional myocardial metabolism and function during brief coronary artery occlusions", Laboratory Investigation, vol. 75, pp. 473-481, (1987).
Benner, K. U., et al., "Uber die Wirkung von Pluronic.RTM. F-68, einem polyoxypropylene-Poloxyathylen-Kondensat, auf die ADP-induzierte Thrombocytenaggregation in vitro", Pflugers Arch., vol. 315, pp. 45-52, (1970).
Forman, M. D., et al., "Reduction of infarct size with intracoronary perfluorochemcial in canine preparation of reperfusion", Circulation, vol. 71, pp. 1060-1068, (1985).
Forman, M. B., et al., "Beneficial long-term effect on intracoronary perfluorochemcial on infarct size and ventricular function in a canine reperfusion model", J. Am. Col. of Cardiol., pp. 1082-1090, (May, 1987).
Goodman, R. L., et al., "Perfluorocarbon emulsions in cancer therapy: preliminary observation on presently available formulations"Int. J. Radiation Oncology biol. Phys., vol. 10, pp. 1421-1424, (1984).
Technical bulletin entitled "Performance Chemicals".
Technical Bulletin entitled "Pluronic.RTM. Block copolymer surfactants".
Perfluorochemical Blood Substitutes, Technical Information Ser. No. 5, Jun. 30, 1978, Revised, Jul. 1, 1981. Manufacturer: The Green Cross Corporation.
Patent Cooperation Treaty International Search Report for PCT Patent Application No. PCT/US87/01067.
Patent Cooperation Treaty International Search Report for the PCT Patent Application No. PCT/US867/01747.
Emory University
Rollins John W.
LandOfFree
Method for treating vascular obstructions caused by abnormal cel does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating vascular obstructions caused by abnormal cel, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating vascular obstructions caused by abnormal cel will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1187701